Anti-interleukin 5 therapies failure criteria in severe asthma: a Delphi-consensus study.

MLA

Mattei, Laura, et al. “Anti-Interleukin 5 Therapies Failure Criteria in Severe Asthma: A Delphi-Consensus Study.” Therapeutic Advances in Respiratory Disease, Jan. 2021, pp. 1–14. EBSCOhost, https://doi.org/10.1177/17534666211049735.

APA

Mattei, L., Suehs, C. M., Alagha, K., Bourdin, A., Brousse, C., Charriot, J., Devouassoux, G., Fry, S., Guilleminault, L., Gouitaa, M., Taille, C., Chanez, P., & Pahus, L. (2021). Anti-interleukin 5 therapies failure criteria in severe asthma: a Delphi-consensus study. Therapeutic Advances in Respiratory Disease, 1–14. https://doi.org/10.1177/17534666211049735

Chicago

Mattei, Laura, Carey M. Suehs, Khuder Alagha, Arnaud Bourdin, Christophe Brousse, Jeremy Charriot, Gilles Devouassoux, et al. 2021. “Anti-Interleukin 5 Therapies Failure Criteria in Severe Asthma: A Delphi-Consensus Study.” Therapeutic Advances in Respiratory Disease, January, 1–14. doi:10.1177/17534666211049735.